The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
these things called ASOS which is really the first treatment that is designed specifically to lower LP little-a so the ASO stands for antisense oligonucleotide so these are molecules that disrupt protein synthesis
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
and in that study they also showed that uh 90 of patients who were treated on that dose had lpa levels below 50 milligrams per deciliter
to your point we have anti sensolo nucleotide Inhibitors that are just around the corner that effectively will get rid of LP little a they shut the gene off so why would we risk trying to iate this from the population when we can just give you a drug that does the same thing with fewer side effects and less permanence